Cite this answer
Desmopressin: quick citable summary
Desmopressin is listed by PeptaHub as a other peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Desmopressin: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/desmopressin. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/desmopressin.
What is Desmopressin?
Desmopressin (DDAVP) is a synthetic vasopressin analog FDA-approved since 1978 for central diabetes insipidus, nocturnal enuresis, hemophilia A, and von Willebrand disease type 1. Modifications at two positions increase antidiuretic potency 8-10 fold while virtually eliminating vasopressor activity.
Overview
Desmopressin (DDAVP) is a synthetic analogue of the endogenous posterior pituitary hormone arginine vasopressin (AVP), modified at two positions: deamination of the N-terminal cysteine (1-desamino) and substitution of L-arginine with D-arginine at position 8. These changes increase antidiuretic potency 8–10 fold, extend half-life 2–4 fold, and virtually eliminate vasopressor activity. FDA-approved since 1978 across multiple formulations, Desmopressin is the standard of care for central diabetes insipidus, nocturnal enuresis, hemophilia A, and von Willebrand disease type 1.
Mechanism of action
Desmopressin acts as a selective V2 vasopressin receptor agonist with minimal V1 receptor activity. V2 receptor activation in renal collecting duct principal cells triggers Gs-coupled adenylyl cyclase activation, elevating intracellular cyclic AMP. cAMP activates protein kinase A, which phosphorylates aquaporin-2 (AQP2) water channels, driving their translocation from cytoplasmic vesicles to the apical membrane. The resulting increase in apical membrane water permeability allows passive water reabsorption from urine into the hyperosmotic medullary interstitium, concentrating urine and reducing urine volume. In hemostasis, V2 receptor activation in vascular endothelial cells triggers release of stored von Willebrand factor (vWF) from Weibel-Palade bodies and increases plasma factor VIII levels through stabilization by vWF, correcting the coagulation defect in mild hemophilia A and type 1 von Willebrand disease.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| central diabetes insipidus (oral) | oral | 0.05–0.4 mg | two to three times daily | Start 0.05 mg twice daily, titrate based on urine output and osmolality. Total daily dose typically 0.1–0.8 mg in divided doses. |
| nocturnal enuresis (nasal) | nasal | 10–40 mcg | once nightly | Standard dose 20 mcg intranasally at bedtime. Restrict fluid intake 1 hour before through 8 hours after dosing to prevent hyponatremia. |
| hemophilia A / von Willebrand disease (IV/SC) | subcutaneous | 0.3–0.3 mcg/kg | single dose pre-procedure | 0.3 mcg/kg IV infused over 15–30 minutes or SC. Repeat dosing risks tachyphylaxis due to vWF store depletion. Maximum response after 30–90 minutes. |
| hemophilia A / von Willebrand disease (IV) | intravenous | 0.3–0.3 mcg/kg | single dose pre-procedure | Infuse over 15–30 minutes. Monitor blood pressure during infusion. Repeat doses may have diminished effect. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Desmopressin research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
Desmopressin has extensive clinical evidence across decades of use. Randomized controlled trials in nocturnal enuresis demonstrate 60–70% reduction in bedwetting nights versus placebo. Central diabetes insipidus management trials confirm near-complete restoration of normal urine output and osmolality. In hemophilia A, desmopressin produces 3–5-fold increases in plasma factor VIII suitable for minor surgical prophylaxis in mild-moderate disease. A 2022 FDA-approved low-dose sublingual tablet (Nocdurna) extended the indication to nocturia due to nocturnal polyuria in adults. Long-term use carries risk of hyponatremia, particularly in children and elderly patients, requiring careful fluid restriction.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Desmopressin for synergistic effects.
Legal status
FDA-approved since February 1978. Available as intranasal spray (DDAVP Nasal Spray), oral tablets (DDAVP Tablets), sublingual tablets (Nocdurna), and IV/SC injection (DDAVP Injection). Multiple generic formulations available. Prescription required in the US and most jurisdictions. Some OTC availability in certain countries for bedwetting formulations.
Sourcing & access
Prescription required
Desmopressin is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus (reducing excessive urination), nocturnal enuresis (bedwetting), and as a hemostatic agent for mild hemophilia A and type 1 von Willebrand disease. It is available as nasal spray, oral tablets, sublingual tablets, and injection.
Desmopressin selectively activates V2 vasopressin receptors in renal collecting ducts, triggering aquaporin-2 water channel translocation to increase water reabsorption and concentrate urine. In hemostasis, it releases stored von Willebrand factor from endothelial cells and increases plasma factor VIII levels.
The most serious risk is hyponatremia (low sodium), especially in children and elderly, requiring fluid restriction during use. Other side effects include headache, nausea, abdominal cramps, facial flushing, and nasal congestion. Seizures can occur secondary to severe hyponatremia.
Desmopressin is available as DDAVP Nasal Spray, DDAVP Tablets, Nocdurna sublingual tablets (for nocturia), Stimate high-concentration nasal spray (for bleeding disorders), and DDAVP Injection for IV or subcutaneous use. Multiple generic formulations exist.
Research references
- Vasopressin analog DDAVP in the treatment of diabetes insipidusPubMed
- Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerationsPubMed
- Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trialPubMed
- A systematic review of the efficacy and safety of desmopressin for nocturia in adultsPubMed